U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CPG Sec. 335.300 Hypnotherapy Devices - Self Hypnotic Tape Recordings
  1. Search for FDA Guidance Documents


CPG Sec. 335.300 Hypnotherapy Devices - Self Hypnotic Tape Recordings



FDA has both seized self-hypnotic tape recordings and issued regulatory letters to manufacturers concerning such recordings because the intended use of the tapes (gathered from both the tapes and their labeling) made them devices within the *Federal Food, Drug, and Cosmetic Act's* definition of a device. The *center's* position is that the tapes are misbranded because of false *or* misleading medical claims in the accompanying promotional literature. Furthermore, the *center* contends that these tapes are prescription devices and adequate directions for lay use cannot be written for these devices.

Hypnotherapy is a recognized medical modality useful for diagnostic and therapeutic purposes. Tape recordings used in conjunction with hypnotherapy which are intended for use in the mitigation, treatment, and cure of disease and other medical conditions are "devices" as that term is defined in Section 201(h) of the act.

Tape recordings labeled only for behavior modification, self-improvement, habit correction, learning techniques, and simple relaxation are not considered to be devices unless they are also labeled for medical or therapeutic use.


The Agency will not object to the distribution of tape recordings provided the labeling and the text of the recordings do not contain claims for specific disease conditions or therapeutic use. The intended use of the tape recordings as medical devices can be established from the labeling and statements made in the tapes themselves that the tapes have therapeutic and medical usefulness.

Tape recordings, the labeling and text of which claim that the tapes are effective as a form of hypnotherapy (including self-hypnosis) and are intended for use in the mitigation, treatment or cure of a specific disease or medical condition, will be regarded as misbranded devices when sold for lay use.

Examples of objectionable claims for lay use are listed below:

Acne and skin problems
Birth Control
Control of Allergies
Emotional health
Hair loss
Hearing Loss
High blood pressure
Hyperactive children
Improving vision
Menstrual Control
Migraine headaches
Pain Control
Psychic healing
Wart Removal

*The district should consider submitting a recommendation for misbranding to the *Office of Compliance (HFZ-300)* when tapes with such claims are offered for lay use. Refer to Compliance Policy Guide 7150.10, Health Fraud - Factors in Considering Regulatory Action, *(Please Note: The Health Fraud definition includes the "... promotion, advertisement, distribution or sale of articles, intended for human or animal use ...")* for guidance. The appropriate charges are 502(a), in that the labeling is false *or* misleading because the articles are not effective for such use and 502(f)(1) in that the articles fail to bear adequate directions for use since adequate directions for use cannot be written for use by laymen of the articles for the purposes for which the devices are intended and they are not exempt from the requirements of section 502(f)(1) of the act and 21 CFR 801.109.*

For Rx use, district offices should contact the *Office of Compliance (HFZ-300)* for guidance before submitting a recommendation.

*Material between asterisks is new or revised*

Issued: 11/01/81
Revised: 11/21/88, 3/95


Submit Comments

Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All comments should be identified with the title of the guidance.

Back to Top